Catherine Bollard, MD, MBChB
Disclosures: Ownership interest (excluding diversified mutual funds)-Neximmune|Co-founder and SAB member-Mana Therapeutics|Board member and stock options-Caballetta Bio|Advisory board and honorarium-Cellectis

Catherine Bollard, MBChB, MD, FRACP, FRCPA

Bosworth Chair for Cancer Biology

Director, Center for Cancer and Immunology Research

Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine

Director, Program for Cell Enhancement and Technologies for Immunotherapy

Children’s National Health System

The George Washington University School of Medicine and Health Sciences

Washington, DC

 

 

Catherine Bollard received her medical degree at the University of Otago in Dunedin, New Zealand. She is Board certified both in Pediatrics and Hematology.  She worked in New Zealand and London, England before moving to Houston in 2000 where she was Professor of Pediatrics, Medicine and Immunology at Baylor College of Medicine (BCM) and Director of the Texas Children’s Cancer and Hematology Center Pediatric Lymphoma Program. In August 2013, she moved to Washington DC to join Children’s National Health System and The George Washington University School of Medicine and Health Sciences. She is currently the Bosworth Chair for Cancer Biology, Director of the Center for Cancer and Immunology Research, and Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) at Children’s National Health System. She is a Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine at The George Washington University and Associate Center Director for Translational Research and Innovation at the GW Cancer Center. She is a member of the American Society for Clinical Investigation (ASCI) and is the immediate Past President of the International Society for Cellular Therapy (ISCT) and has chaired the Non Hodgkin Lymphoma (NHL) Committee of the Children’s Oncology Group since 2012. She was on the Board of Directors of the Foundation in for the Accreditation of Cellular Therapy (FACT) from 2010-2018 and was a member of the Cellular, Tissues and Gene Therapies Advisory Committee of the Food and Drug Administration (FDA) from 2015-2019. In 2019 she became a member of the Frederick National Laboratory Advisory Committee (FNLAC) for the NIH and an ad hoc member of the Pediatric Oncologic Drugs Advisory Committee (ODAC) for the FDA. She has been an Associate Editor for the journal Blood since 2014 and recently completed her six year term on NCI’s Clinical Oncology (CONC) Study Section. Her bench and translational research focuses on improving outcomes for patients after hematopoietic stem cell transplantation and on the development of novel cell therapies for viral diseases and hematologic malignancies.